Dermata promotes Nardo to Chief Development Officer; CEO takes 20% pay cut

Dermata Therapeutics, Inc.

Christopher Nardo promoted to SVP, Chief Development Officer effective July 1, 2022.
Nardo granted option for 30,000 shares; vests 25% after one year, then monthly over 36 months.
Nardo's base salary increased to $320,000 from $280,000 per year.
CEO Gerald Proehl reduces salary from $350,000 to $280,000 per year effective same date.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Christopher J. Nardo

Senior Vice President, Chief Development Officer

DRMA · Dermata Therapeutics, Inc.

Effective: 2022-07-01
Filed: June 24, 2022, 7:59 PM ET

Christopher J. Nardo, Ph.D., the Company’s Senior Vice President of Development, was promoted to Senior Vice President, Chief Development Officer, effective July 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher J. Nardo changed role as Senior Vice President, Chief Development Officer at Dermata Therapeutics, Inc..

Action: promoted
Role: Senior Vice President, Chief Development Officer

Exact text from the filing

Christopher J. Nardo, Ph.D., the Company’s Senior Vice President of Development, was promoted to Senior Vice President, Chief Development Officer, effective July 1, 2022.

View on SEC.gov

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-22-008770

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.